Bausch + Lomb publishes real-world study on enVista Aspire lenses

Wed, 02 Sep 2026 07:01:35 -0400

Bausch + Lomb Corporation (NYSE: BLCO) announced the publication of a multicenter retrospective case series examining real-world outcomes with its enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study appeared in the journal Ophthalmology and Therapy.

The study involved six U.S.-based cataract surgeons and included 84 patients and 141 eyes — 88 implanted with enVista Aspire and 53 with enVista Aspire toric. Surgeons completed a retrospective experience survey capturing visual acuity, refractive outcomes, and safety data.

In the enVista Aspire group, 97.2% of patients achieved a monocular corrected distance visual acuity (CDVA) of 20/25 or better, 71.3% achieved uncorrected distance

Bausch + Lomb publishes real-world study on enVista Aspire lenses

Wed, 02 Sep 2026 07:01:35 -0400

In the enVista Aspire group, 97.2% of patients achieved a monocular corrected distance visual acuity (CDVA) of 20/25 or better, 71.3% achieved uncorrected distance

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Wed, 02 Sep 2026 07:00:00 -0400

Multicenter retrospective case series published in Ophthalmology and Therapy
Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of patients
Study shows these enhanced monofocal lenses can meet digital demands modern cataract patients face
This paper and other data on enVista Aspire can be found on Bausch + Lomb’s new Eye Care Professional Hub

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Wed, 02 Sep 2026 07:00:00 -0400

Multicenter retrospective case series published in Ophthalmology and Therapy

Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of patients

Study shows these enhanced monofocal lenses can meet digital demands modern cataract patients face

This paper and other data on enVista Aspire can be found on Bausch + Lomb’s new Eye Care Professional Hub

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Wed, 02 Sep 2026 07:00:00 -0400

Multicenter retrospective case series published in Ophthalmology and Therapy

Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of patients

Study shows these enhanced monofocal lenses can meet digital demands modern cataract patients face

This paper and other data on enVista Aspire can be found on Bausch + Lomb’s new Eye Care Professional Hub

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Wed, 02 Sep 2026 07:00:00 -0400

Multicenter retrospective case series published in Ophthalmology and Therapy

Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of patients

Study shows these enhanced monofocal lenses can meet digital demands modern cataract patients face

This paper and other data on enVista Aspire can be found on Bausch + Lomb’s new Eye Care Professional Hub

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Wed, 02 Sep 2026 07:00:00 -0400

Multicenter retrospective case series published in Ophthalmology and Therapy

Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of patients

Study shows these enhanced monofocal lenses can meet digital demands modern cataract patients face

This paper and other data on enVista Aspire can be found on Bausch + Lomb’s new Eye Care Professional Hub

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Wed, 02 Sep 2026 07:00:00 -0400

Multicenter retrospective case series published in Ophthalmology and Therapy

Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of patients

Study shows these enhanced monofocal lenses can meet digital demands modern cataract patients face

This paper and other data on enVista Aspire can be found on Bausch + Lomb’s new Eye Care Professional Hub

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Tue, 01 Sep 2026 06:58:00 -0400

Only 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom.
78% of women were surprised to learn that dry eye is a symptom of perimenopause or menopause.
Women experiencing dry eye reported impacts on everyday activities including reading, screen use, driving and productivity.
Findings underscore the need for greater awareness of the connection between menopause and eye health.

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Tue, 01 Sep 2026 06:58:00 -0400

Only 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom.
78% of women were surprised to learn that dry eye is a symptom of perimenopause or menopause.
Women experiencing dry eye reported impacts on everyday activities including reading, screen use, driving and productivity.
Findings underscore the need for greater awareness of the connection between menopause and eye health.

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Tue, 01 Sep 2026 06:58:00 -0400

Only 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom.
78% of women were surprised to learn that dry eye is a symptom of perimenopause or menopause.
Women experiencing dry eye reported impacts on everyday activities including reading, screen use, driving and productivity.
Findings underscore the need for greater awareness of the connection between menopause and eye health.

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Tue, 01 Sep 2026 06:58:00 -0400

Only 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom.
78% of women were surprised to learn that dry eye is a symptom of perimenopause or menopause.
Women experiencing dry eye reported impacts on everyday activities including reading, screen use, driving and productivity.
Findings underscore the need for greater awareness of the connection between menopause and eye health.

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Tue, 01 Sep 2026 06:58:00 -0400

Only 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom.
78% of women were surprised to learn that dry eye is a symptom of perimenopause or menopause.
Women experiencing dry eye reported impacts on everyday activities including reading, screen use, driving and productivity.
Findings underscore the need for greater awareness of the connection between menopause and eye health.

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Tue, 01 Sep 2026 06:58:00 -0400

Only 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom.
78% of women were surprised to learn that dry eye is a symptom of perimenopause or menopause.
Women experiencing dry eye reported impacts on everyday activities including reading, screen use, driving and productivity.
Findings underscore the need for greater awareness of the connection between menopause and eye health.

H.C. Wainwright Reiterates Buy Rating on Bausch & Lomb Corp. (BLCO)

Fri, 28 Aug 2026 07:04:23 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $21.00 price target on Bausch & Lomb Corp. (NYSE: BLCO).

The analyst commented: 'Earlier this week, Bausch + Lomb reported clinical data from two of its pipeline assets, including dual-action eye drop for dry eye disease (DED) and a topical TRPV1 antagonist (BL1332) for ocular surface pain. While the Phase 2 trial of the dual-action eye drop did not meet its primary endpoint at Day 29, secondary analysis data at Day 15 enable the company to advance the candidate into a Phase 3 program in 2027. The Phase 1b trial of

Bausch & Lomb Corp. (BLCO) Reiterated at Hold by Stifel on Mixed Ph2 Data for Xiidra+Miebo

Tue, 25 Aug 2026 07:08:06 -0400

Stifel analyst Jonathan D. Block reiterated a Hold rating and $16.00 price target on Bausch & Lomb Corp. (NYSE: BLCO).

The analyst commented, "BLCO announced mixed ph2 data for its dual-action dry eye topical (Xiidra+Miebo), which did not meet its primary endpoint of superiority versus Xiidra at Day 29 (change from baseline in total corneal fluorescein staining). However, it did achieve superiority over Xiidra at Day 15, which is a timepoint accepted by FDA —and as a result, BLCO will advance the dual-action drop into ph3 studies.The 2xdaily dosing of the dual-action drug (versus 2x Xiidra and 4x Miebo) may resonate

Bausch + Lomb advances two eye drop candidates to new trials

Mon, 24 Aug 2026 16:30:48 -0400

Bausch + Lomb Corporation (NYSE: BLCO) announced that two investigational eye treatments will move to new clinical stages following recent trial results, according to a company press release.

The first candidate is a dual-action eye drop that combines 5% lifitegrast and perfluorohexyloctane (PFHO) into a single twice-daily treatment targeting both ocular surface inflammation and tear evaporation in dry eye disease. A Phase 2 study enrolling 443 patients did not meet its primary endpoint of superiority over lifitegrast alone in reducing total corneal fluorescein staining at Day 29. A pre-specified secondary analysis at Day 15 showed a statistically significant reduction versus lifitegrast

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results